文献速递基础与转化研究新药、器械与细胞基因治疗研发

抗CD19 CAR-T细胞治疗儿童难治性自身免疫病

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.
PubMed 文献 · Nat Med · 2026-02-05

该病例系列报告了8例难治性自身免疫病患儿(4例系统性红斑狼疮、3例皮肌炎、1例系统性硬化症)接受单次输注1×10^6 kg^-1自体CD19 CAR-T细胞(zorpocabtagene autoleucel)的治疗结果。中位随访16.5个月(范围9-24个月)时,全部患儿病情显著改善或缓解,且不良事件均为1级。

要点

  • 8例难治性儿童自身免疫病患者接受单次CD19 CAR-T输注后均获得临床显著改善或缓解。
  • 不良事件以1级细胞因子释放综合征为主(6例),未见严重感染。
  • 病情改善使患儿得以持续停用免疫调节剂,即使B细胞已重建。

核心结论

  • 单次输注zorpocabtagene autoleucel可使难治性儿童自身免疫病获得临床显著改善或缓解,且不良事件可控。

研究设计与样本

  • 病例系列研究,纳入8例在罗马Ospedale Pediatrico Bambino Gesù和埃尔朗根大学医院接受治疗的严重/难治性自身免疫病患儿。
  • 在医院豁免(HE)项目下,单次输注1×10^6 kg^-1即时制备的自体CD19 CAR-T细胞(zorpocabtagene autoleucel)。

主要发现

  • 所有患者制备均成功,输注后CAR-T细胞在体内扩增并促进B细胞清除。
  • 6例报告1级细胞因子释放综合征,1例报告1级免疫效应细胞相关神经毒性综合征。
  • 2例出现1级迟发性血液毒性,所有不良事件均可管理,无严重感染发生。
  • 中位随访16.5个月(范围9-24个月),全部患者疾病活动度评分降低并出现器官损伤逆转迹象。
  • 病情改善使患者得以持续停用免疫调节剂,即使在B细胞重建后。

临床怎么用

  • 对于缺乏有效治疗选择的难治性儿童自身免疫病患者,CD19 CAR-T细胞治疗可作为医院豁免项目下的个体化治疗选择。
  • 治疗过程中需监测细胞因子释放综合征、免疫效应细胞相关神经毒性综合征和迟发性血液毒性,但本系列中均为1级且可控。

局限性

  • 本文为病例系列研究,样本量小(8例),随访时间有限(中位16.5个月,范围9-24个月)。
  • 作者指出亟需开展正式临床试验以确认初步结果并评估长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cell therapy was recently proposed as a treatment for adults with B-cell-mediated autoimmune diseases (ADs) refractory to conventional immunomodulatory therapy. We present a case series of eight children with severe/refractory AD (four systemic lupus erythematosus, three dermatomyositis, one systemic sclerosis) treated at Ospedale Pediatrico Bambino Gesù, Rome, and University Hospital Erlangen with a single infusion of 1 × 106 kg-1 point-of-care manufactured autologous CD19 CAR T cells (zorpocabtagene autoleucel), in a hospital exemption (HE) program. In Europe, the HE pathway offers the opportunity to treat patients with life-threatening or seriously debilitating disorders who lack valid therapeutic options, using an advanced therapy medicinal product (ATMP) authorized on a nonroutine, single-patient basis. In contrast to the 'compassionate use' pathway, the ATMP does not necessarily need to have undergone clinical trials or marketing authorization applications. Manufacturing was successful in all patients, yielding several drug product bags. Once infused after lymphodepletion, zorpocabtagene autoleucel cells expanded in vivo, promoting prompt B cell clearance. Grade 1 cytokine release syndrome was reported in six patients, and grade 1 immune effector cell-associated neurotoxicity syndrome was reported in one patient. Late-hematotoxicity was limited to grade 1 in two patients. All these adverse events were manageable and no severe infections occurred. With a median follow-up of 16.5 months (range = 9-24 months), all patients experienced a clinically substantial improvement/resolution of AD, as evidenced by reduction in disease activity scores and signs of reversal of organ damage. This improvement enabled sustained discontinuation of immunomodulators, even after B cell reconstitution. The activation of formal clinical trials enrolling children and adolescents is urgently needed to confirm these preliminary results and to assess the long-term safety of this approach.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Becilli M, Metzler M, Bracaglia C, et al. Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases. Nat Med. 2026. PMID: 41644747. doi:10.1038/s41591-025-04191-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。